Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BloXaphte is an over-the-counter oral care product line developed by Dr. Gerhard Mann (a subsidiary of Bausch + Lomb) for the treatment of aphthae (canker sores), oral lesions, and inflammatory injuries to the oral mucosa. Classified as a medical device rather than a traditional pharmaceutical, it functions by forming a protective physical film over the affected areas, which provides rapid pain relief and promotes the healing of painful spots in the mouth. The product line includes various formulations such as an oral care spray, a mouth gel for adults, and a junior gel for children. The formulations are sugar-free, alcohol-free, and paraben-free, containing ingredients like hyaluronic acid, panthenol, and aloe vera to support mucosal recovery without known drug interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BloXaphte.